Taylors Provide $10 Million to Accelerate Psychiatric Drug Development

Taylors Provide $10 Million to Accelerate Psychiatric Drug Development
I​n 2012, Andrew and Barbara Taylor and the Crawford Taylor Foundation pledged $20 million to the Department of Psychiatry at Washington University’s School of Medicine to establish a research institute dedicated to advancing new treatments for mental illnesses. Just six years later, investigators in the department’s Taylor Family Institute for Innovative Psychiatric Research are on […]

Taylor family establishes $10 million scholarship challenge

Taylor family establishes $10 million scholarship challenge
A $10 million commitment from Andrew Taylor, a life trustee at Washington University in St. Louis, and his wife, Barbara, will establish the Taylor Family Scholarship Challenge, which will match all new and increased gifts for undergraduate scholarships received by the conclusion of Leading Together: The Campaign for Washington University on June 30, 2018, as well as […]

New approach to developing antidepressants

New approach to developing antidepressants
In the new research, Steve Mennerick, Institute scientific director, and his colleagues focused on GABA receptors located on neurons in the brain’s hippocampus, a part of the brain involved in learning and memory. Using CRISPR, they mutated the delta-type GABA receptors to isolate and test their role in brain functioning.

Cicero receives Pioneer Award

Theodore J. Cicero, PhD, the John P. Feighner Professor of Psychiatry at Washington University School of Medicine in St. Louis, is the 2018 recipient of the Pioneer Award from the National Council on Alcoholism and Drug Abuse (NCADA).

Laughing gas studied as depression treatment

Nitrous oxide, or laughing gas, has shown early promise as a potential treatment for severe depression in patients whose symptoms don’t respond to standard therapies. The pilot study was believed to be the first research in which patients with depression were given laughing gas.